Literature DB >> 15190493

Pathology of the sentinel lymph node in melanoma.

Hans Starz1.   

Abstract

The success and further evolution of the sentinel lymph node (SLN) concept decisively depend on histological techniques. Fundamental standards were agreed on by a panel of international experts from various disciplines in 1999 and published as "The Augsburg Consensus" in 2000. Conventional histology (hematoxylin and eosin [H&E]) has to be supplemented by immunohistochemistry (eg, S100 and HMB45) using adequate series of paraffin sections. Melanoma cells in SLNs must be carefully differentiated from capsular and trabecular nevocytes, from immigrated Langerhans cells, from interdigitating dendritic leukocytes, and from nerve sheath cells, which all share S100 positivity in the cytoplasm. The micromorphometric S classification is based on the maximum distance of intranodal melanoma cells from the interior margin of the SLN capsule. It has proven its practicability under routine circumstances, as well as its predictive value regarding further nodal and distant metastases as well as overall survival. This has to be considered in prospective randomized trials dealing with the issues of completion lymphadenectomy and adjuvant therapies of melanoma patients. Reverse-transcriptase polymerase chain reaction (RT-PCR) techniques, when performed as a supplement to histology on the basis of additional paraffin sections, can further enhance the diagnostic sensitivity for detecting melanoma cells in SLNs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15190493     DOI: 10.1053/j.seminoncol.2004.03.011

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

1.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.

Authors:  Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 9.236

Review 2.  Primary Melanoma: from History to Actual Debates.

Authors:  Alessandro A E Testori; Stephanie A Blankenstein; Alexander C J van Akkooi
Journal:  Curr Oncol Rep       Date:  2019-12-19       Impact factor: 5.075

3.  Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.

Authors:  Rajmohan Murali; Alistair J Cochran; Martin G Cook; Joseph D Hillman; Rooshdiya Z Karim; Marc Moncrieff; Hans Starz; John F Thompson; Richard A Scolyer
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

4.  SLN melanoma micrometastasis predictivity of nodal status: a long term retrospective study.

Authors:  Emilia Migliano; Barbara Bellei; Flavio Andrea Govoni; Giovanni Paolino; Caterina Catricalà; Stefania Bucher; Pietro Donati
Journal:  J Exp Clin Cancer Res       Date:  2013-08-01

5.  Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR).

Authors:  Richard A Scolyer; Meagan J Judge; Alan Evans; David P Frishberg; Victor G Prieto; John F Thompson; Martin J Trotter; Maureen Y Walsh; Noreen M G Walsh; David W Ellis
Journal:  Am J Surg Pathol       Date:  2013-12       Impact factor: 6.394

Review 6.  Surgery and radiotherapy in the treatment of cutaneous melanoma.

Authors:  A Testori; P Rutkowski; J Marsden; L Bastholt; V Chiarion-Sileni; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.